Circulating Tumor Cell Market Size and Analysis, Trends, Share and Forecast Till 2027

The global circulating tumor cell market is anticipated to touch USD 28,300 million at a favorable CAGR between 2018-2023, states the latest Market Research Future (MRFR) report. Circulating tumor cells or CTCs, simply put, are cells that have detached from the primary tumor and circulates in the bloodstream. They act as the seed for cancer metastases. CTCs are extremely useful in determining the status of the disease progression rate as well as the projection of therapy required for tumor eradication. 

Various factors are propelling the circulating tumor cell market growth. Such factors, according to the latest Market Research Future report, include growing demand for companion diagnostics and preventive medicine, advancements in bioengineering technology and biomedical imaging, increasing incidence of lifestyle-induced diseases especially obesity and diabetes, increasing R&D expenditure, favorable initiatives undertaken by the government, aging population, and increasing need for oncology screening, diagnosis as well as diagnostic options to eradicate cancer completely from the infection site. Additional factors propelling the growth of the circulating tumor cell market include the rising use of advanced medicine, increasing allocation of budget for the healthcare sector, better technological growth, increasing prevalence of cancer, and vital role of translational research and genomics to create methods to improve detection, enumeration as well as analysis of circulating tumor cell in patient specimens.

On the other hand, unwillingness to adopt these technologies, lack of awareness regarding advanced technologies, and the high price of treatment are factors that may deter the circulating tumor cell market growth during the forecast period. 

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1362

Market Segmentation

The Market Research Future report provides an all-inclusive segmental analysis of the circulating tumor cell market based on application, end use, and technology.

By technology, the circulating tumor cell market is segmented into combined enrichment & separation of CTC, CTC detection, and CTC enrichment. Of these, the CTC enrichment segment will lead the market during the forecast period for its wide use in oncology research. 

By application, the circulating tumor cell market is segmented into drug development, research, and clinical. Of these, the research segment will dominate the market during the forecast period. 

By end use, the circulating tumor cell market is segmented into diagnostic centers, research and academic institutes, and hospitals and clinics. Of these, hospitals and clinics will hold the maximum share in the circulating tumor cell market during the forecast period. 

Regional Analysis

By region, the circulating tumor cell market report covers the latest trends and growth opportunities across the Asia Pacific, North America, the Middle East and Africa, and Europe. Of these, North America will dominate the market during the forecast period. Various factors propelling the growth of the circulating tumor cell market in the region include the presence of a healthcare sector in the region that is highly advanced, increasing incidence of cancer, and rising efforts to enhance and update the means of combating the same. 

The circulating tumor cell market in the APAC region will have a steady growth during the forecast period for the rising prevalence of cancer and rising healthcare expenditure, especially in emerging countries. 

The circulating tumor cell market in Europe will have favorable growth during the forecast period for the increasing number of patients being admitted for cancer treatment and technological advancements in the UK, Germany, and France. 

The circulating tumor cell market in the MEA will have moderate growth during the forecast period for less per capita income and poor healthcare infrastructure.

Key Players

Notable players profiled in the circulating tumor cell market report include Greiner Bio-One International GmbH, SRI International, Miltenyi Biotec, QIAGEN, NanoString Technologies Inc., GE Healthcare, Advanced Cell Diagnostics Inc. (Bio-Techne Corporation), Celltraffix Inc., Epic Lifesciences, ApoCell, Fluxion Biosciences Inc., F. Hoffman-La Roche Ltd., Menarini Silicon Biosystems, STEMCELL Technologies, Thermo Fisher Scientific, and Ikonisys Inc.

Industry News

October 2019: RareCye has launched the RarePlex Developer Kits, which uniquely allow customers to add their biomarkers to the RareCyte CTC (circulating tumor cell) assays in their own lab. 

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/circulating-tumor-cell-market-1362

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Have a Look at Related Reports:

Contact and Intraocular Lenses Market

Central Nervous System Biomarkers Market

Tags: Circulating Tumor Cell Market Size, Circulating Tumor Cell Market Share, Circulating Tumor Cell Market Scope, Circulating Tumor Cell Market Trends, Circulating Tumor Cell Market Forecast See Campaign: https://www.marketresearchfuture.com/reports/circulating-tumor-cell-market-1362

Contact Information:

Contact us: Market Research Future (part of Wantstats Research and Media Private Limited), 99 Hudson Street, 5Th Floor, New York, New York 10013 United States of America +1 628 258 0071 Email: [email protected]

Tags:
PR-Wirein, Wire, Research Newswire, English